Corporate Presentations • Actinogen
XanaMIA Part A Trial positive topline results for Xanamem – Webcast 27 April 2022
Actinogen announced positive topline results for its XanaMIA Part A trial involving its small molecule drug Xanamem on 27 April 2022. Watch the recording here of the webcast and Q&A session hosted by CEO Dr Steven Gourlay and CMO Professor Paul Rolan to get a more in-depth picture about this exciting news for the company.
27 Apr 2022